Dr. John Shen, a medical oncologist at UCLA and an investigator on APEX-01, comments on the updated data from the ongoing Phase 1/2 APEX-01 trial of ARX517 in mCRPC presented at #ESMO23. For details: bit.ly/3tM8e6v $AMAM #ProstateCancer

Updated safety, efficacy and PK data from Ambrx’s on-going Phase 1/2 trial, APEX-01, evaluating ARX517 for mCRPC, were made available in clinical posters as part of #ESMO23. For data highlights: bit.ly/3tM8e6v $AMAM #ProstateCancer

Dr. Sartor, a medical oncologist and translational researcher with 33 yrs of professional experience and a special focus on #prostatecancer, comments on the newly published data from the ongoing Ph. 1/2 APEX-01 trial of ARX517 in mCRPC presented at #ESMO23 bit.ly/3tM8e6v

.FierceBiotech highlighted the recent data presented at #ESMO23 from the ongoing Phase 1/2 APEX-01 trial of the #AntibodyDrugConjugate ARX517 in mCRPC showing anti-cancer activity and few adverse events—none serious. Read more: bit.ly/495pyDP $AMAM #ProstateCancer

In newly published data from Ambrx's ongoing Ph. 1/2 APEX-01 trial of ARX517 in mCRPC presented at #ESMO23, ARX517 was shown to display preliminary efficacy & a strong safety profile in patients with mCRPC. Read more from OncLive.com: bit.ly/46NXjYy $AMAM #ProstateCancer

Company News: Ambrx's CEO & CSO discuss the antibody-drug conjugate space and recent #ESMO23 data. $AMAM Full video: biotechtv.com/post/ambrx-nov…

Ambrx's CEO & CSO spoke with @BiotechTVHQ's Brad Loncar about our two #AntibodyDrugConjugate programs, ARX788 Anti-HER2 ADC and ARX517 Anti-PSMA ADC, both of which are potential treatments for cancer indications with high unmet medical need. bit.ly/3MuDRYC $AMAM

Thank you to all who attended Ambrx's KOL event discussing the ARX517 data presented at the 2023 European Society for Medical Oncology Congress meeting. A webcast replay of the event is available here: bit.ly/475J7dj $AMAM #ESMO23 ESMO - Eur. Oncology #ProstateCancer

This Sunday, November 5th, Ambrx will walk to raise awareness for #breastcancer at the 2023 San Diego Susan G. Komen #MoreThanPink walk. Learn about the event and join our team here: bit.ly/3u6bUzX #BreastCancerAwareness

Dr. Shen spoke with OncLive.com about the unique features associated with the use of Ambrx's PSMA–directed #AntibodyDrugConjugate ARX517 in patients with mCRPC and highlighted data presented at #ESMO23 from the ongoing Phase 1/2 APEX-01 trial of ARX517. bit.ly/473VzKK $AMAM

Ambrx today announced a clinical update regarding its proprietary anti-PSMA ADC ARX517 in the ongoing APEX-01 Phase 1/2 dose escalation and dose expansion clinical trial in metastatic castration resistant #prostatecancer (mCRPC). For details: bit.ly/410TRaP $AMAM

Our Chief Clinical Officer, Sandra Aung, Ph.D., comments on Ambrx's ongoing Phase 1/2 trial, APEX-01, evaluating ARX517 for metastatic castration resistant #prostatecancer (mCRPC). Read more: bit.ly/410TRaP $AMAM

Updated results from the Phase 1/2 APEX-01 clinical trial of ARX517 demonstrate continued safety and anti-tumor activity in patients with metastatic castration-resistant #prostatecancer (#mCRPC). Read more in Urology Times. bit.ly/484KUj0 $AMAM #AntibodyDrugConjugate

ARX517, Ambrx's PSMA–directed #AntibodyDrugConjugate (ADC), demonstrated promising safety and efficacy in the APEX-01 trial in patients with #mCRPC. No serious adverse events or DLTs were observed in the Phase 1/2 clinical trial. Read more bit.ly/3t56Agg $AMAM

Thank you Dana-Farber’s Breast Oncology Center for highlighting our poster at #SABCS23 on ACE-Breast-03, our Ph. 2 study of ARX788 in HER2+ #metatastaticbreastcancer patients previously treated with trastuzumab deruxtecan. We look forward to sharing updates on this important work. #breastcancer $AMAM

Ambrx today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023. For more information: bit.ly/3GEum65 $AMAM $NBI

Our CEO Dan O'Connor comments on Ambrx's transformational year and the Company's addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). Learn more: bit.ly/3GEum65 $AMAM $NBI

We entered into a definitive agreement to be acquired by Johnson & Johnson. We are excited to join a global organization & accelerate our promising pipeline of next-gen ADCs for patients in need of targeted treatment options. For more info & cautionary statements: bit.ly/3NVXqKl

Ambrx is now officially part of J&J Innovative Medicine. With our world-class team and novel ADC product candidates, we have exciting opportunities ahead to advance and deliver novel targeted therapies for patients with cancer. Read here: investor.jnj.com/news/news-deta…